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SA striking result of this study is the finding that cellular
inhibition of group IIa sPLA2 in lung cancer cells decreases
the production of the enzyme itself. Potential mechanisms
could be through decreased transcriptional regulation either
by the enzyme itself or through downstream products. In ad-
dition, lung cancer cell apoptosis increases with prolonged
exposure to sPLA2 inhibition.
17 The combination of
decreased invasion and cancer cell viability from sPLA2
inhibition favors its potential as a therapeutic agent. As
specific group IIa sPLA2 inhibitors have already been stud-
ied in clinical trials for rheumatoid arthritis and sepsis,
their potential application in malignancy is particularly
appealing.24,25
The mechanism of sPLA2 inhibition on ICAM-1 expres-
sion is likely dependent on the transcription factor nuclear
factor-kB.9,10,16 Elucidation of intracellular pathways
affected by group IIa sPLA2 inhibition in lung cancer
cells is the topic of ongoing research.
In summary, these data suggest that sPLA2 plays a signif-
icant role in mediating the inflammatory signals that induce
ICAM-1 expression in lung cancer cells. In addition, this
study demonstrates that pharmacologic inhibition of the en-
zyme can significantly decrease ICAM-1 expression and
subsequent cancer cell invasion. This lays the groundwork
for further investigation into the cellular mechanisms of
sPLA2 and the effect of sPLA2 on lung cancer proliferation
in vitro and in vivo.References
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DrMichael Mulligan (Seattle, Wash). Congratulations on your
paper and a very nice presentation. I always appreciate seeing a lot
of effort put intowork, and clearly you did that. I noticed the article
that your group put out via e-publication last month evaluating
ICAM regulation with sPLA2 in esophageal cancer cells, and
this is a nice extension of that work. It is always difficult to
know what the next great research question is and you seem to
be onto something here.
I have 3 questions, which I will ask one at the time.
The matrigel assay is used to screen cell lines and measure in-
vasiveness, but ultimately it is a dead matrix and is devoid of either
known or candidate ligands for ICAM-1. If you do a quick search,
you can find that there is now a body of researchers who are look-
ing at ICAM-1 not so much as an adhesion receptor, particularly in
the invasion paradigm, but as a signaling molecule. That is a littleery c February 2012
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Sbit different. Indeed, your findings suggest that your greatest
effects on invasiveness were with direct inhibition of ICAM-1
and not with sPLA2 inhibition indirectly, thereby affecting expres-
sion of ICAM-1. Can you postulate how ICAM-1 is regulating
invasiveness? Is it merely adjusting the phenotype or something
more invasive, or how does blockade of ICAM-1 allow you to
digest through a collagen matrix differently than without?
Dr Yu. ICAM-1 can be considered a phenotype of invasive
cells. How it helps the tumor cells invade through the matrix or,
more important, in an in vivo model promote metastatic disease,
is not well defined. There are other mediators of invasion that
we did not necessarily address here, such as metalloproteinases
that help digest the matrix. ICAM-1 is a reasonable marker of in-
vasion given all of the evidence in serum and in tumor tissue. There
are always limitations to in vitro studies, and I think the next move
is to try sPLA2 inhibition in an in vivo model.
Dr Mulligan. It is exciting because with direct blockade you
definitely showed an effect; yet there is no ICAM ligand in the as-
say, so it has to be signaling somehow. There is a lot of potential
there for another award.
The second question relates to specificity and loss of specificity
with S3319, also known as KHO64. If you look at the dose ranges
or the therapeutic concentrations for most of the small molecule
targeted interventions that we use, like Tarceva (Hoffmann-La
Roche, Basel, Switzerland) or any other ‘‘nibs,’’ they are always
in the low nanomolar range, yet you were using up to 40 mmol/L.
What data do you have to assess for loss of specificity or potential
off-target effects?
DrYu. It is difficult to correlate concentrations that are used invi-
tro with an eventual in vivo concentration. One thing we did do was
look at the cytotoxicity of the small molecule inhibitor in the lung
cancer cells using a lactic dehydrogenase cytotoxicity assay. All
the concentrations and time points we used were viable for the cells.The Journal of Thoracic and CaDrMulligan.However, you are seeing something weird, too, in
that you are seeing an enzyme inhibitor having a sort of an auto-
crine reverse effect on transcription of the enzyme itself. It could
be that you have disrupted all sorts of transcriptional mechanisms
that you just have not tracked yet, so it would be good to go back
and look at that.
The last question is a more global one. Activation of sPLA2 is
a fairly upstream activation event, particularly if you try to relate
it to ICAM-1 activation. There are a lot of intervening steps., in-
cluding activation of cyclooxygenase. For the past 20 years there
has been a lot of work looking at inhibition of those intermediate
steps that should theoretically work reasonably well, but they do
not work. I found about 100 publications or more this morning
that demonstrated efficacy in cell systems and more than 50 clin-
ical trials that showed that nothing worked when they tried to take
it forward.What makes this different?Why should this work and is
it safe? Because it is such an omnipresent enzyme that has so many
functions, if we knock it out, what are we going to do to the wild
type or to the patient?
Dr Yu. sPLA2 is upstream. One of the interesting things about
this particular enzyme is that it generates arachidonic acid, but it
also has someother effects. For example, sPLA2 can function as a li-
gand and not just as an intracellular enzyme. These other functions
may be targeted with inhibition of sPLA2. In terms of sPLA2 being
used in humans andwhether or not it is toxic, sPLA2 inhibitors have
been used in trials for rheumatoid arthritis and sepsis. There were
no noticeable toxicities. Finally, regarding the idea that there could
be a single shot approach to addressing anything involving cancer
or invasiveness in particular, sPLA2 inhibition is useful as a research
tool and may eventually be part of multimodality therapy targeting
different pathways that promote malignancy.
Dr Mulligan. Perhaps this is one pathway but maybe not the
pathway.rdiovascular Surgery c Volume 143, Number 2 411
